Antipsychotic medications, schizophrenia and the issue of quality of life

Quality of Life Impairment in Schizophrenia, Mood and Anxiety Disorders: New Perspectives on Research and Treatment

Volumn , Issue , 2007, Pages 307-319

  Awad, A George ^a   Voruganti, Lakshmi N P ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Antipsychotics; Conceptual models; Dopamine; Neurobiological correlates; Quality of life; Quality of life scales; Schizophrenia

Indexed keywords

EID: 34848822764     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4020-5779-3_16     Document Type: Chapter

References (76)

1. Davies L.M., Drummond M.F. The Economic Burden of Schizophrenia. Psychiat. Bull 1990; 14: 522-555.
2. Awad A.G., Voruganti L.N.P., Heselgrave R.J. The Aim of Antipsychotic Medications: What Are They and Are They being Achieved? CNS Drugs 1995; 4: 8-16.
3. Arana G.W. An Overview of Side Effects Caused by Typical Antipsychotics. J. Clin Psychiatry; 2000; 61 (Suppl 8): 5-11.
4. Awad A.G. Antipsychotic Medications: Compliance and Attitudes Towards Treatment. Curr. Opin. Psychiatry. 2004; 17: 75-80.
5. Awad A.G., Masty V., McDonnell D. The Link Between Drug Attitudes, Compliance Behaviour and Resource Use Among Individual with Schizophrenia. Poster Presented at the 150 2nd American Psychiatric Association Meeting 1999; (Washington, D.C.).
6. Kerwin R.W., Taylor D. New Antipsychotics: A Review of their Current Status and Clinical Practice. CNS Drugs 1996; 6: 71-82.
7. Awad A.G., Voruganti L.N.P. New Antipsychotics, Compliance, Quality of Life, and Subjective Tolerability-Are Patients Better Off? Can J Psychiatry 2004; 49: 297-302.
8. Lieberman J., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe, R., Davis C., Severe J., Hsiao J., and the Catie Investigators. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. The New England J. MED; 353: 1209-1223.
9. Voruganti L.N.P., Cortese L., Owyeumi L., Kotteda V., Cernovsky Z., Zirul S., Awad A.G. Switching from Conventional to Novel Antipsychotic Drugs: Results of a Prospective Naturalistic Study. Schizophr. Res 2002; 57: 201-208.
10. Wirshing D.A., Spellberg P.J., Erhart S.M., Marder S.R., Wirshing W.C. Novel Antipsychotic and New Onset Diabetes. Biol. Psychiatry 1998; 44: 778-783.
11. Newcomer J.W. Second Generation (atypical) Antipsychotic and Metabolic Effects: A Comprehensive literature Review. CNS Drugs 2005; 19: 1-93.
12. De Nayer, DeHert M., Scheem A., Van Gaal L., Peuskins J., Conference Report: Belgain Consensus on Metabolic Problems Associated with Second Generation Antipsychotics. Int J. Psychiatry Clin Pract. 2005; 9: 130-137.
13. Rothbard A., Murrin M.R., Jordon N., Kuno E., McFarland B., Stroup T.S., Morrissey J.P., Stiles P., Boothroyd R., Merwin E., Shern D. Effects of Antipsychotic Medication on Psychiatric Service Utilization and Cost. J Ment Health Policy Econ 2005; 8:83-93.
14. Awad A.G. Voruganti L.N.P., Heselgrave R.J., Preliminary Validation of a Conceptual Model to Assess Quality of Life in Schizophrenia. Quality of Life Res, 1997; 6: 21-26.
15. Lambert M., Naber D. Current Issues in Schizophrenia: Overview of Patient Acceptability, Functioning Capacity and Quality of Life. CNS Drugs 2004; 18: 5-17.
16. Norman R.M., Malla A.K., McLean T., The Relationship of Symptoms and Level of Functioning in Schizophrenia to General Wellbeing and the Quality of Life Scale. Acta Psychiatr Scand 2000, 102: 303-309.
17. Barowne S, Clarke M, Gervin M., Waddington J.L., Larkin C., O'Callaghan B., Determinants of Quality of Life at First Presentation with Schizophrenia. Br. J. Psychiatry 2000; 176: 173-176.
18. Karow A., Naber D., Subjective Wellbeing and Quality of Life under Atypical Antipsychotic Treatment. Psychopharmacology 2002; 162: 3-10.
19. Ritsner M., Kurs R., Impact of Antipsychotic agents and their Side Effects on the Quality of Life in Schizophrenia. Expert Rev. Pharmacoeconomics Outcomes. Res. 2002; 2: 89-98.
20. Awad A.G., Antipsychotic Medications in Schizophrenia: How Satisfied are our Patients? In Hellewell J. Editor: Clear Perspectives 1999, 2: 1-6. London, Shire Hall International.
21. Voruganti L.N.P., Heselgrave R.J., Awad A.G., Seeman M., Quality of Life Measurement in Schizophrenia: Reconciling the question for subjectivity with the question of Reliability.
22. Kilian R., Angermeyer M.C., The Effect of Antipsychotic Treatment on Quality of Life of Schizophrenic patients under naturalistic Treatment conditions: An application of random effect regression models and propensity scores in an observational prospective trail. Quality of Life Res 2005; 14: 1275-1289.
23. Awad A.G., Lapierre Y.D., Augus C., Rylander A., Quality of Life and Response of Negative Symptoms in Schizophrenia to Haloperidol and the Atypical Antipsychotic Remoxipride J. Psychiatry Neurosci. 1997; 22: 244-248.
24. Ritsner M, Kurs R., Gibel A., Hirshchmann S., Shinkarenko E., Ratner Y., Predictors of Quality of Life in Major Psychosis: A Naturalistic Follow up Study. J. Clin Psychiatry 2003; 64: 308-315.
25. Ritsner M., Ben-Avi I., Ponizovsky A., Timinsky I Bistrov E., Modai I., Quality of Life and Coping with Schizophrenic Symptoms. Quality Life Res. 2003; 12: 1-9.
26. Awad A.G., Voruganti L.N.P., Impact of Atypical Antipsychotics on Quality of Life in Patients with Schizophrenia. CNS Drugs 2004; 18: 877-893.
27. Corrigan P.W., Reinke R., Landsberger S.A., Charate A., Toombs G.A. The Effect of Atypical Antipsychotic Medications on Psychosocial Outcome Schizophr Res 2003; 63: 91-101.
28. Awad A.G. Voruganti L.N.P., Heselgrave R.J., Measuring Quality of Life in Patients with Schizophrenia. Pharmacoeconomics 1997; 11: 32-47.
29. Jeste D.V., Klausner M, Brecher M., Clyde C., Jone R. Clinical Evaluation of Risperidone in the Treatment of Schizophrenia: A 10 week Open Label Muticentre Trial. Psychopharmacology 1997; 131: 239-247.
30. Barcia D., Ayuso J.L, herraiz M.L. Calidad de vida en Pacientes Esquizofrenicos Tratados con Risperidona. An Psiquiatr 1996; 12: 403-412.
31. Voruganti L.N.P., Cortese L., Oyewumi L.K., Cernovsky Z., Zirul S., Awad A.G. Comparative Evaluation of Conventional and New Antipsychotic Drugs with reference to their subjective Toler-ability, Side Effect, Profile and Impact on Quality of Life. Schizophr. Res. 2000; 43: 135-145.
32. Bobes J., Gutierrez M., Gibert J. et al. Quality of Life in Schizophrenia: Long Term Follow-up in 362 Chronic Spanish Schizophrenic Outpatients undergoing Risperidone Maintenance Treatment. Eur Psychiatry 1998; 13: 158-163.
33. Franz M., Lis S., Pluddemann K., et al. Conventional vs. Atypical Neuroleptic: Subjective Quality of Life in Schizophrenia Patients. Br J Psychiatry 1997; 170: 422-425.
34. Hamilton S.H., Revicki D.A., Edgell E.T., et al. Clinical and Economic Outcomes of Olanzapine compared with Haloperidol for Schizophrenia: Results from a Randomized Clinical Trial. Pharma-coeconomics 1999; 15: 469-480.
35. Revicki D.A., Ginduso L.A., Hamilton S.H., et al. Olanzapine vs. Haloperidol in the Treatment of Schizophrenia and Other Psychotic Disorders: Quality of Life and Clinical Outcomes of a Randomized Clinical Trial. Qual Life Res 1999; 8: 417-426.
36. Tran P.V., Hamilton S.H., Kunz A.J., et al. Double-Blind Comparison of Olanzapine vs. Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders. J Clin Psychopharmacology 1997; 17: 407-418.
37. Ho B.C., Miller D., Nopoulos P., et al. A Comparative Effectiveness Study of Risperidone and Olanzapine in the Treatment of Schizophrenia. J Clin Psychiatry 1999; 60: 658-663.
38. Naber D., Moritz S., Lambert M., et al. Improvement of Schizophrenic Patients' Subjective well-being under Atypical Antipsychotic Drugs. Schizophr Res 2001; 50: 79-88.
39. Tempier R., Pawliuk N. Influence of Novel and Conventional Antipsychotic Medication on Subjective Quality of Life. J Psychiatry Neuroscience 2001; 26: 131-136.
40. Strakowksi S., Johnson J., DeBello M., Hamer R., Green A., Tohen M., Lieberman J., Glick I., Patel J., Quality of Life during Treatment with Haloperidol or Olanzapine in the year following a first psychotic Episode. Schizophr Res 2005; 78: 161-169.
41. Awad A.G. First Episode Psychosis: Olanzapine and Haloperidol provide similar improvement in Quality of Life and Social Functioning; Commentary Evidence-Based Mental Health 2006; 9:47.
42. Meltzer H.Y., Burnett S., Bastani B., et al. Effects of Six months of-Clozapine Treatment on the Quality of Life of Chronic Schizophrenic Patients. Hosp Community Psychiatry 1990; 41: 892-897.
43. Meltzer H.Y., Okayli G., Reduction of Suicidality during Clozapine Treatment of Neuroleptic-resistant Schizophrenia: Impact on Risk Benefit Assessment. Am J Psychiatry 1995; 152: 183-190.
44. Naber D. A self-rating to Measure Subjective Effects of Neuroleptic Drugs, Relationships to Objective Psychopathology, Quality of Life, Compliance and other Clinical Variables. Int Clin Psychopharmacology 1995; 10 Suppl. 3: 133-138.
45. Rosenheck R., Cramer J., Xu W., et al. A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia. N Engl J Med 1997; 337: 809-815.
46. Bellack A.S., Schooler N.R., Marder S.R., Kane J.M., Brown C.H., Young Y. Do Clozapine and Risperidone Affect Social Competence and Problem Solving? Am J Psychiatry 2004; 16: 364-367.
47. Essock S.M., Hargreaves W.A., Covell N.H. et al. Clozapine's Effectiveness for Patients in State Hospitals: Results from a Randomized Trial. Psychopharmacology Bull 1996; 32: 683-697.
48. Hellewell J.S. Kalai A.H., Langham S.J. et al. Patient Satisfaction and Acceptability of Long-Term Treatment with Quetiapine. Int J Psychiatry Clin Pract 1999; 3: 105-113.
49. Addington D.E., Jons B., Bloom D. Reduction of Hospital Days in Chronic Schizophrenic Patients treated with Risperidone: A Retrospective Study. Clin Ther 1993; 15: 917-926.
50. Albright P.S., Livingston S., Keegan D.L. Reduction of Health Care Resource Utilization and Cost following the use of Risperidone for patient with Schizophrenia previously treated with Standard Antipsychotic Therapy: A Retrospective Analysis using the Saskatchewan Health Linkage database. Clin Drug Invest 1996; 11: 289-299.
51. Reid W.H., Mason M., Toprac M. Saving in hospital bed days related to treatment with Clozapine. Hosp. Community Psychiatry 1994; 45: 261-263.
52. Dickson R.A. Hospital Days in Clozapine Treated Patients. Can J. Psychiatry 1998; 43: 945-948.
53. Awad A.G., Voruganti L.N.P. Cost-Utility Analysis in Schizophrenia. J. Clin Psychiatry 1999; 60 suppl. 3: 22-26.
54. Voruganti L.N.P., Awad A.G., Oyewumi L.K. Assessing Health Utilities in Schizophrenia: A feasibility Study. Pharmacoeconomics 2000; 17: 273-286.
55. Dernovsek M.Z., Prevolnik-Rupel V., Tavcar R. Cost Utility Analysis Research and Practical Applications (Chapter).
56. Hargreaves W.A., Shumway M. Pharmacoeconomics of Antipsychotic Drug Therapy. J. Clin Psychiatry 1996; 57: suppl. 9: 66-76.
57. Revicki D. Pharmacoeconomic Studies of Atypical Antipsychotic Drugs for the Treatment of Schizophrenia. Schizophr. Res 1999; 35: 101-109.
58. Zito J.M. Pharmacoeconomics of the New Antipsychotics for the Treatment of Schizophrenia. Psychiatric Clin. North A.M. 1998; 21: 181-202.
59. Green M.F., What are the Functional Consequences of Neurocognitive Deficits in Schizophrenia? Am J Psychiatry 1996; 153: 321-330.
60. Keefe R., Poe M., Waker T., Kang J., Harvey P.H. The Schizophrenia Cognition Rating Scale: An interview based Assessment and its Relationship to Cognition, real-work functioning and functional capacity. Am J Psychiatry 2006; 163: 426-432.
61. Velligan D.I., Mahurin R.K., Diamond P.L., Hazelton B.C., Eckert S.L., Miller A.L. The Functional Significance of Symptomatology and Cognitive Function in Schizophrenia. Schizophr Res 1997; 25: 21-31.
62. Heselgrave R.J., Awad A.G. Voruganti L.N.P., The Influence of Neurocognitive deficits and symptoms on Quality of Life in Schizophrenia. J. Psychiatry Neuroscience 1997; 22: 235-243
63. Moritz S., Ferahli S., Naber D. Memory and Attention Performance in Psychiatric patients: Lack of correspondence between Clinician-rated and patient-rated functioning with neuropsychological test results. J. Int Neuropsychol Soc. 2004; 10: 623-633.
64. Bowie C., Reichenberg A., Patterson T., Heaton R., Harvey P. Determinants of Real-World Functional Performance in Schizophrenia Subjects: Correlations with Cognition, Functional Capacity and Symptoms. Am J Psychiatry 2006; 163: 418-425.
65. Hooker C., Park S. Emotion processing and its relationship to Social Functioning in Schizophrenic Patients. Psychiatry Res 2002; 112: 41-50.
66. Wise R.A. Addictive Drugs and Brain Stimulation Reward. Ann Rev Neurosci. 1996; 19: 319-340.
67. Fibiger H.C. Neurobiology of Depression-focus on Dopamine. Adv Biochem Psychopharma-cology 1995; 49: 1-7.
68. Voruganti L.N.P., Slomka P., Zabel P., Costa G., So A., Mattar A., Awad A.G. Subjective Effects of AMPT induced Dopamine Depletion in Schizophrenia. The Correlation between D2 binding ration and Dysphoric Responses. Neuropsychopharmacology 2001; 25: 642-650.
69. de Hann L, Lavalaye J., Linszen D., Dingemans P.M.A.J., Booij J. Subjective Experiences and Striatal Dopamine D2 Receptor Occupancy in Patients with Schizophrenia stabilized by Olanzapine or Risperidol. Am J Psychiatry 2000; 157: 1019-1020.
70. Voruganti L.N.P., Awad A.G. Subjective and Behavioural Consequences of Striatal Dopamine Depletion in Schizophrenia-findings from an in VIVO SPECTS study. Schiz Res (in press)
71. Voruganti L.N.P., Awad A.G. Role of Dopamine in Pleasure, Reward and Subjective responses as Important aspects of Quality of Life. (Chapter 2)
72. Gill T.M., Feinstein A.R. A Critical Appraisal of the Quality of Quality of Life Measurements. JAMA 1994; 272: 619-626.
73. Awad A.G. Voruganti L.N.P. Intervention Research in Psychosis: Issues related to the Assessment of Quality of Life. Schizophr Bull 2000; 26: 557-564.
74. Awad A.G., Voruganti L.N.P. The Subjective/objective dichotomy in Schizophrenia: Relevance to nosology, research and management. In: Gaebel W., editor. Zukunftsperspktiven in Psychiatries Und Psychotherapie. Darmstadt: Steinkopff Verlag, 2002: 21-27.
75. Skantze K., Malm U., Dencker S.J., May P.R.A., Corrigan P. Comparison of Quality of life with standard of living in Schizophrenic Out-patients. Br J. Psychiatry 1992; 161: 797-801.
76. Skantze K. Subjective Quality of Life and Standard of living: A 10-year Follow up of Out-patients with Schizophrenia. Acta Psychiatr Scand. 1998; 98: 390-399.